查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1968488

短腸症候群市場－全球產業規模、佔有率、趨勢、機會、預測：依藥物類別、通路、地區和競爭格局分類，2021-2031年

Short Bowel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球短腸症候群市場預計將從 2025 年的 8.5402 億美元成長到 2031 年的 12.6237 億美元，複合年成長率為 6.73%。

該市場涵蓋治療生物製藥和藥物，例如生長激素和類升糖素肽-2類似物，旨在改善接受過廣泛小腸切除術患者的營養吸收並促進腸道適應。推動該市場成長的主要因素是需要手術介入和持續管理的嚴重胃腸道疾病（例如腸系膜缺血和克隆氏症）的盛行率不斷上升。此外，旨在減少對腸外營養依賴、改善生活品質和臨床療效的標靶治療的研發也促進了該市場的發展。

市場概覽
預測期 2027-2031
市場規模：2025年 8.5402億美元
市場規模：2031年 1,262,370,000 美元
複合年成長率：2026-2031年 6.73%
成長最快的細分市場 線上銷售
最大的市場 北美洲

根據美國腸外經腸營養學會 (ASPN) 2024 年的數據，全球短腸症候群相關腸道功能障礙的盛行率估計為每 10 萬成年人 0.12 至 2.74 例。儘管有這樣的需求，市場面臨著許多障礙，包括先進藥物和長期治療的高昂費用。這種沉重的經濟負擔造成了巨大的報銷難題，尤其是在醫療基礎設施尚不完善的情況下，限制了患者的就醫途徑，並有效地阻礙了這些新型醫療方案的廣泛應用。

市場促進因素

新型GLP-2類似物療法的商業化和應用正在從根本上改變全球短腸症候群市場，減少患者終身依賴腸外營養的情況。這些先進的生物製藥模擬天然腸道激素，促進腸道適應，並顯著降低維持生命所需的靜脈輸液頻率和輸液量。這些治療方法的快速普及凸顯了臨床上迫切需要找到解決方案來減輕與長期使用導管相關的併發症。這一發展動能體現在主要市場參與者的成功上，例如武田藥品工業株式會社。該公司在2024年5月發布的「2023會計年度業績報告」中指出，其旗艦產品Gatex/Levestiv在2023會計年度的銷售額達到7.96億美元。這主要得益於較高的治療維持率和患者可近性的提高。

同時，新一代療法的強勁臨床開發平臺正在推動市場發展，其中長效製劑的推出減輕了患者每日注射的負擔。製藥公司正致力於研發每週一次的治療方案，與目前的治療標準相比，這些方案有望提高患者的依從性和生活品質。作為這項進展的佐證，Ironwood Pharmaceuticals在2024年2月的新聞稿中宣布，其在研藥物apraglutide與治療前方案相比，每週腸外營養支持量減少了25.5%。這些創新正瞄準高價值的市場區隔。 Ironwood預計，到2024年，歐洲、日本和美國約有18,000名成年人患有伴隨腸道功能障礙的短腸症候群，並認為這些新興治療方法蘊藏著巨大的市場機會。

市場挑戰

先進藥物治療和長期療法的高昂費用是全球短腸症候群市場成長的主要障礙。慢性腸外營養和特殊生物製藥的高昂價格導致醫保支付方面臨諸多阻力，往往導致嚴格的報銷通訊協定和頻繁的拒付。這種經濟負擔迫使醫療機構僅在最難治或嚴重的病例中使用新療法，阻礙了產品的推廣。因此，在醫療基礎設施低度開發、公共資金不足以支持此類昂貴終身治療的地區，市場擴張舉步維艱。

保險公司和病患的這種經濟負擔與市場擴張受限直接相關。 2024年，PAN基金會報告稱，在其短腸症候群經濟援助計劃下，已向符合條件的患者提供了18,200美元的首批津貼。這凸顯了一個現實：即使是受保人用戶也面臨高昂的自付費用。如此沉重的經濟負擔會阻礙患者繼續治療，並限制創新醫療方案的商業性應用，從而抑制整個產業的獲利能力。

市場趨勢

家庭腸外營養服務的擴展正將長期照護的重心從臨床環境轉移到住宅環境，旨在提高患者的生活品質並降低醫院相關成本。這一趨勢使慢性腸道功能障礙的管理分散化，使患者能夠在獲得必要營養支持的同時維持日常生活。然而，供應鏈不穩定和營運成本上升威脅著這種模式的永續性。根據美國家庭輸液協會於2025年8月發布的一份白皮書，2016年至2024年間，家庭經腸營養產品的製備成本預計將以每年75.4%的速度成長，這將為尋求擴展這些基本服務的機構帶來沉重的經濟負擔。

同時，拓展兒童適應症已成為一項重要的策略驅動力，製藥公司正擴大其臨床目標，以惠及先前服務不足的兒童患者群體。透過兒童用藥的監管核准，製造商正在建立早期療育通訊協定，以減輕短腸症候群對兒童發育的長期影響，這種策略不同於以往僅關注成人的策略。這種向更年輕族群的策略轉變正在帶來實際的經濟效益。根據 PharmaLive 2025 年 10 月的一篇報導，武田製藥的 Gatex/Levestiv 在 2024 會計年度的銷售額成長了 22.6%，達到 9.66 億美元。這一成長動能顯然歸功於兒童適應症拓展所帶來的需求成長。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球短腸症候群市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（GLP-2、麩醯胺酸、生長激素）
    • 分銷管道（醫院藥房、線上銷售、零售藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美短腸症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲短腸症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區短腸症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲短腸症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美短腸症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球短腸症候群市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Dentsply Sirona Inc.
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19143

The Global Short Bowel Syndrome Market is projected to expand from USD 854.02 Million in 2025 to USD 1262.37 Million by 2031, registering a CAGR of 6.73%. This market encompasses therapeutic biologics and pharmaceuticals, such as growth hormones and glucagon-like peptide-2 analogs, aimed at improving nutrient absorption and facilitating intestinal adaptation in patients who have experienced significant small bowel resection. The primary catalyst for this growth is the rising prevalence of serious gastrointestinal conditions, including mesenteric ischemia and Crohn's disease, which require surgical intervention and ongoing management. Furthermore, the market is being bolstered by the creation of targeted therapies designed to decrease reliance on parenteral nutrition, thereby offering enhanced quality of life and better clinical results.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 854.02 MIllion
Market Size 2031USD 1262.37 MIllion
CAGR 2026-20316.73%
Fastest Growing SegmentOnline Sales
Largest MarketNorth America

According to data from the American Society for Parenteral and Enteral Nutrition in 2024, the diagnosed prevalence of intestinal failure associated with short bowel syndrome was estimated at 0.12 to 2.74 per 100,000 adults worldwide. Despite this demand, the market faces a major obstacle in the form of prohibitive costs linked to advanced pharmacological treatments and long-term therapies. This high financial burden results in significant reimbursement challenges and restricts patient access, particularly within developing healthcare infrastructures, which effectively constrains the widespread adoption of these novel medical solutions.

Market Driver

The commercialization and adoption of novel GLP-2 analog therapies is fundamentally transforming the Global Short Bowel Syndrome Market by lessening patient dependence on lifelong parenteral nutrition. These advanced biologics simulate natural gut hormones to encourage intestinal adaptation, which significantly lowers the frequency and volume of intravenous fluids needed for survival. The rapid uptake of these treatments highlights a critical clinical need for solutions that reduce complications related to chronic catheter use. This momentum is reflected in the success of major market players; for instance, Takeda's May 2024 'FY2023 Full Year Results' reported that sales for its leading therapy, Gattex/Revestive, hit $796 million for the fiscal year 2023, fueled by high adherence rates and broadened patient access.

Simultaneously, a robust clinical pipeline of next-generation therapeutics is driving the market forward by introducing long-acting formulations designed to remove the burden of daily injections. Pharmaceutical developers are focusing on once-weekly dosing regimens expected to enhance patient compliance and quality of life relative to current care standards. As evidence of this progress, Ironwood Pharmaceuticals announced in a February 2024 press release that their investigational drug apraglutide achieved a 25.5 percent relative decrease in weekly parenteral support volume. These innovations target a high-value niche; Ironwood estimated in 2024 that Short Bowel Syndrome with Intestinal Failure affects approximately 18,000 adults across Europe, Japan, and the U.S., presenting a concentrated opportunity for these emerging treatments.

Market Challenge

The exorbitant costs associated with advanced pharmacological treatments and long-term therapy act as a major barrier to the growth of the Global Short Bowel Syndrome Market. The high price tags for chronic parenteral nutrition and specialized biologics cause significant friction with payers, often leading to stringent reimbursement protocols and frequent claim denials. This financial toxicity compels healthcare providers to restrict the prescription of novel therapies to only the most refractory or severe cases, effectively stifling product uptake. Consequently, the market struggles to expand in regions with developing healthcare infrastructures where public funding is inadequate to support such premium, lifelong treatments.

This economic burden on insurers and patients directly correlates with limited market expansion. In 2024, the PAN Foundation reported that its financial assistance program for Short Bowel Syndrome provided an initial grant of $18,200 to eligible patients, underscoring the substantial out-of-pocket costs faced even by those with insurance. Such a high level of financial liability discourages patient adherence and restricts the commercial reach of innovative medical solutions, thereby capping revenue potential throughout the sector.

Market Trends

The expansion of home-based parenteral nutrition services is shifting long-term care priorities from clinical settings to residential environments, aiming to enhance patient quality of life and cut hospital-related costs. This trend decentralizes the management of chronic intestinal failure, enabling patients to maintain their daily routines while receiving necessary nutritional support. However, the sustainability of this model is threatened by supply chain instability and rising operational expenses. A white paper released by the National Home Infusion Association in August 2025 noted that the cost of preparing home parenteral nutrition formulations rose by a compounded 75.4 percent between 2016 and 2024, placing significant economic strain on providers trying to scale these essential services.

Concurrently, a strategic focus on pediatric label expansions is emerging as a key growth driver, with pharmaceutical companies broadening their clinical targets to include the underserved pediatric population. By obtaining regulatory approvals for children, manufacturers are establishing early intervention protocols designed to mitigate the long-term developmental effects of short bowel syndrome, differentiating their strategies from purely adult-focused approaches. This pivot toward younger demographics is delivering tangible financial gains; according to an October 2025 PharmaLive article, sales for Takeda's Gattex/Revestive increased by 22.6 percent to $966 million in fiscal year 2024, a growth trajectory explicitly attributed to demand from pediatric indication label expansions.

Key Market Players

  • Dentsply Sirona Inc.
  • Emmaus Life Sciences, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • OPKO Health, Inc.
  • OxThera AB
  • Pfizer Inc.
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Report Scope

In this report, the Global Short Bowel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Short Bowel Syndrome Market, By Drug Class

  • GLP-2
  • Glutamine
  • Growth Hormone

Short Bowel Syndrome Market, By Distribution Channel

  • Hospital Pharmacies
  • Online Sales
  • Retail Pharmacies

Short Bowel Syndrome Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Short Bowel Syndrome Market.

Available Customizations:

Global Short Bowel Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Short Bowel Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (GLP-2, Glutamine, Growth Hormone)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Online Sales, Retail Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Short Bowel Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Short Bowel Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Short Bowel Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Short Bowel Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Distribution Channel

7. Europe Short Bowel Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Short Bowel Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Short Bowel Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Short Bowel Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Short Bowel Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Short Bowel Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Short Bowel Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Short Bowel Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Short Bowel Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Short Bowel Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Short Bowel Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Short Bowel Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Short Bowel Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Short Bowel Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Short Bowel Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Short Bowel Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Distribution Channel

10. South America Short Bowel Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Short Bowel Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Short Bowel Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Short Bowel Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Short Bowel Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Dentsply Sirona Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Emmaus Life Sciences, Inc.
  • 15.3. Merck & Co., Inc.
  • 15.4. Novartis AG
  • 15.5. OPKO Health, Inc.
  • 15.6. OxThera AB
  • 15.7. Pfizer Inc.
  • 15.8. Swedish Orphan Biovitrum AB
  • 15.9. Takeda Pharmaceutical Company Limited
  • 15.10. Teva Pharmaceutical Industries Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer